menu
    • menu
    [{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Lynch Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Protein","year":"2025","type":"Acquisition","leadProduct":"Becaplermin","moa":"PDGFR","graph1":"Podiatry","graph2":"Approved FDF","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"SMITH & NEPHEW INC \/ Lynch Regenerative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"SMITH & NEPHEW INC \/ Lynch Regenerative Medicine"},{"orgOrder":0,"company":"Centaur Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diperoxochloric Acid","moa":"Undisclosed","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Centaur Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"Centaur Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Centaur Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"Gunze Medical Limited","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Human Amnion Membrane Allograft","moa":"Undisclosed","graph1":"Podiatry","graph2":"Approved FDF","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"MiMedx \/ Gunze Medical Limited","highestDevelopmentStatusID":"15","companyTruncated":"MiMedx \/ Gunze Medical Limited"},{"orgOrder":0,"company":"MiMedx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Amnion Membrane Allograft","moa":"Undisclosed","graph1":"Podiatry","graph2":"Approved FDF","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"MiMedx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MiMedx \/ Inapplicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Best Buy Medical Canada","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Polyhexanide","moa":"||Acanthamoeba cell membrane","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Best Buy Medical Canada","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Best Buy Medical Canada"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"BioStem Technologies","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Polyhexanide","moa":"||Acanthamoeba cell membrane","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ BioStem Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ BioStem Technologies"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ NRC IRAP","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ NRC IRAP"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Qatar Datamation Systems","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Polyhexanide","moa":"||Acanthamoeba cell membrane","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Qatar Datamation Systems","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Qatar Datamation Systems"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SMITH & NEPHEW INC

                            Canada arrow
                            World Vaccine Conference
                            Not Confirmed

                            SMITH & NEPHEW INC

                            Canada arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Becaplermin

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : Lynch Regenerative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lynch Regenerative Acquires REGRANEX® Gel for Soft Tissue Regeneration

                            Details : Under the acquisition, Lynch holds the exclusive rights to Regranex (becaplermin) gel and recombinant purified platelet-derived growth factor (PDGF). It is being indicated for diabetic foot ulcer.

                            Product Name : Regranex

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            March 31, 2025

                            Lead Product(s) : Becaplermin

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : Lynch Regenerative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kane Biotech

                            Canada arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : Best Buy Medical Canada

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kane Announces Canadian Distribution Agreement with Best Buy Medical for Revyve

                            Details : The agreement aims for the distribution of revyve, an antimicrobial wound gel product line in infection management and wound healing.

                            Product Name : Revyve

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 11, 2025

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : Best Buy Medical Canada

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kane Biotech

                            Canada arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : BioStem Technologies

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Kane Biotech Changes US Partner for Revyve™ Antimicrobial Wound Gel Distribution

                            Details : BioStem Technologies will acquire exclusive US distribution rights for revyve from ProgenaCare Global.

                            Product Name : Revyve

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 27, 2024

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : BioStem Technologies

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kane Biotech

                            Canada arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : Qatar Datamation Systems

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kane Biotech Signs Deal with Qatar Datamation For Wound Gel Distribution

                            Details : The agreement aims for the distribution of revyve antimicrobial wound gel indicated for diabetic foot ulcers, in the Qatar wound care market.

                            Product Name : Revyve

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 28, 2024

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : Qatar Datamation Systems

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kane Biotech

                            Canada arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : NRC IRAP

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Kane Biotech Receives Funding Support to Expand the Revyve Antimicrobial Wound Gel Family

                            Details : The funding will support the development of three additional products to build on Kane Biotech’s revyve Antimicrobial Wound Gel technology for management of ulcers.

                            Product Name : Revye

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 13, 2024

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : NRC IRAP

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kane Biotech

                            Canada arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kane Biotech Receives FDA Approval to Increase Dosage of Revyve™ Wound Gel

                            Details : Revyve Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), burns, partial & full thickness wounds for adult populations.

                            Product Name : Revye

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 23, 2024

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            MiMedx

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MiMedx

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Amnion Membrane Allograft

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : Gunze Medical Limited

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            MIMEDX Announces Commercial Launch of EPIFIX® in Japan with Exclusive Distribution Agreement with Gunze Med...

                            Details : EPIFIX (human amnion membrane allograft) is a PURION® processed placental tissue allograft that supports the healing cascade by providing a semi-permeable, protective barrier over wounds.

                            Product Name : Epifix

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 01, 2023

                            Lead Product(s) : Human Amnion Membrane Allograft

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : Gunze Medical Limited

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kane Biotech

                            Canada arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kane Biotech and ProgenaCare Global Launch Newly Rebranded Revyve™ Antimicrobial Wound Gel at Advanced Wound...

                            Details : revyve™ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult po...

                            Product Name : Revye

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 11, 2023

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            MiMedx

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MiMedx

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Amnion Membrane Allograft

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MIMEDX EPIFIX® Receives Reimbursement Approval in Japan

                            Details : EPIFIX (Human Amnion-chorion Membrane Allograft) is a PURION® processed placental tissue allograft that supports the healing cascade by providing a protective barrier over wounds.

                            Product Name : Epifix

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            December 09, 2022

                            Lead Product(s) : Human Amnion Membrane Allograft

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Centaur Pharmaceuticals

                            India arrow
                            Cophex
                            Not Confirmed

                            Centaur Pharmaceuticals

                            India arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diperoxochloric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Centaur Pharma Launches Novel Topical Solution WoxHeal for the Treatment of Diabetic Foot Ulcer

                            Details : WOXheal has dual mechanism of action, i.e. it has functional antibacterial action against Gram positive and gram negative bacteria and it also promotes growth of fibroblast cells, thereby yielding complete wound closure.

                            Product Name : WOXheal

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 10, 2020

                            Lead Product(s) : Diperoxochloric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth